Skip to content

Study · Animal study (in vivo) · mouse · 2022

3 results

Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide (SS-31) and nicotinamide mononucleotide (NMN) treatment.

Whitson JA, Johnson R, Wang L, Bammler TK, Imai SI, Zhang H, Fredrickson J, Latorre-Esteves E, Bitto A, MacCoss MJ, Rabinovitch PS

GeroScience13 Apr 2022Cited by 10 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In aging mouse hearts, NMN modestly restored age-altered protein abundance and induced additional changes.

    In plain wordsIn mice, NMN modestly restored protein abundance altered by heart aging and caused additional changes.

    Outcome
    MixedProtein abundance
    Study

    mousen: not reported in source

    Aging mouse hearts
    Outcome group
    Aging markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both drugs had a modest effect on restoring the abundance and acetylation of proteins that are altered with age, while also inducing additional changes.
    1 context sentence
    Summary · context
    We analyzed the effects of aging on protein abundance and acetylation, as well as the ability of the mitochondrial-targeted drugs elamipretide (SS-31) and nicotinamide mononucleotide (NMN) to reverse aging-associated changes in mouse hearts.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In aging mouse hearts, NMN modestly restored age-altered protein acetylation and induced additional changes.

    In plain wordsIn mice, NMN modestly restored protein acetylation altered by heart aging and caused additional changes.

    Outcome
    MixedProtein acetylation
    Study

    mousen: not reported in source

    Aging mouse hearts
    Outcome group
    Aging markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both drugs had a modest effect on restoring the abundance and acetylation of proteins that are altered with age, while also inducing additional changes.
    1 context sentence
    Summary · context
    We analyzed the effects of aging on protein abundance and acetylation, as well as the ability of the mitochondrial-targeted drugs elamipretide (SS-31) and nicotinamide mononucleotide (NMN) to reverse aging-associated changes in mouse hearts.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In aged mouse hearts, elamipretide and NMN (reported together) had a modest effect in restoring age-altered protein abundance and acetylation, while inducing additional changes.

    In plain wordsIn old mice, elamipretide and NMN, reported together, partly restored age-related protein changes in the heart and caused other changes.

    Outcome
    MixedAge-related changes in protein abundance and acetylation
    Study

    mousen: not reported in source

    aged mouse heart
    Outcome group
    Aging markers · Aging and longevity

    Source sentences

    Summary
    Both drugs had a modest effect on restoring the abundance and acetylation of proteins that are altered with age, while also inducing additional changes.
    1 context sentence
    Summary · context
    We analyzed the effects of aging on protein abundance and acetylation, as well as the ability of the mitochondrial-targeted drugs elamipretide (SS-31) and nicotinamide mononucleotide (NMN) to reverse aging-associated changes in mouse hearts.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 12Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 9 times, first on 21 Oct 2026, 15:59 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 08:19 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.